Gilead Sciences (GILD)
$66.70
0.11 (0.17%)
GILD Stock Quote Delayed 30 Minutes
5 Biotech Stocks to Play the Sector’s Next Big Trend: NASH
Looking for blockbuster potential? These five biotech stocks may have found it in treating NASH -- an untapped market of up to $35 billion.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
83.63B
PE Ratio
190.57
EPS
0.35
Volume (Avg. Vol.)
4.21M
Day's Range
$66.01 - $66.93
52-Week Range
$62.07 - $87.86
Dividend & Yield
$3.00 (4.50%)
GILD Stock Predictions, Articles, and Gilead Sciences News
These 9 Dividend Stocks Are About to Soar — Thanks to Donald Trump
There’s a lot uncertainty in today’s market, but one thing is guaranteed ... The new tax reform law is about to cause an avalanche of money to rush into dividend stocks in the weeks and months ahead.
3 Big Stock Charts for Monday: Wells Fargo, Philip Morris and Gilead Sciences
The stock charts of Wells Fargo, Philip Morris and Gilead Sciences are shaping up as this week's most compelling prospects.
Trade of the Day: Gilead Sciences (GILD)
There is a lot of uncertainty swirling in the markets, and that’s really the last thing that investors want. However, one stock I’ve had my eye on recently for a bullish play is Gilead Sciences (NASDAQ:GILD), which has jumped from the $72 level to over $76 in just the last three sessions.
Biotech ETFs Are the Best Way to Play the Recovering Sector
The biotech sector peaked in 2015. While it bounced back from lows, biotech ETFs give investors exposure to the sector as it recovers.
FDA Shame List: 40 Drug Makers That Try to Block Generic Drugs
The Food and Drug Administration (FDA) announced a list of drug makers that have tried to block generic drugs in its new shame list. Here they are.
Gilead Sciences, Inc. Stock Will Recover… Eventually
Gilead Sciences, Inc. got walloped following a huge earnings miss. The pieces are in place for GILD stock to make a comeback, but it won't happen quickly.
Thursday’s Vital Data: Snap Inc (SNAP), Gilead Sciences, Inc. (GILD) and Weatherford International plc (WFT)
Snap (SNAP) redesign tanks earnings, Gilead Sciences (GILD) call options popular after earnings miss and Weatherford (WFT) sees massive put option trade.
5 Top Stock Trades for Thursday Morning
Investors are digesting earnings from Apple Inc. and Snap Inc, along with a release from the Federal Reserve. In the meantime, here are our top stock trades for Thursday.
Gilead Sciences, Inc. Stock Declined After Earnings Miss
Gilead Sciences (GILD) shares were falling more than 5% after the bell Tuesday as the company unveiled quarterly earnings results below estimates.
At $79.99, Gilead Sciences (GILD) a Hold
Gilead Sciences (GILD) a Hold at $79.99 based on the most current stock market ratings, and comparative pricing of its shares.
This week, Gilead Sciences (GILD) stays a Hold
At $78.73, Gilead Sciences (GILD) a Hold based on the most recent stock market ratings, and relative pricing of its shares.
Is Gilead Sciences, Inc. Stock Still a Solid Value Play?
Despite a weak fourth-quarter, Gilead Sciences (GILD) stock still has deep value. If its drug studies play out, it could return to growth sooner than expected.
Gilead Sciences, Inc. (GILD) Shares Slide on Weak Outlook
Gilead Sciences (GILD) shares fell slightly after hours as the company's full-year revenue is slated to be below the Wall Street consensus estimate.
